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In response: neuraxial and
peripheral misconnection
events leading to wrong-route
medication errors
To the Editor
We thank Dr Patel for calling attention to his very thoughtful and insightful
reviews of neuraxial and potassium chloride administration errors.1–3 We are
pleased that his work complements and
amplifies the results of our study.4 Our
literature search was performed using
PubMed and Embase, which served as the
primary sources for published references
on misconnection events. To supplement
this, we conducted an internet search
strictly for related public access documents from regulatory bodies such as the
Food and Drug Administration.
The reviews authored by Dr Patel
and colleagues include multiple types of
human errors, while our narrative review
focused on one specific error: the misconnection of intravenous tubes and syringes.
To that end, we specifically omitted
wrong-
route cases attributed to causes
other than misconnection (eg, mislabeled
medication containers) and included
only reports of confirmed misconnection
events that noted the name of the drug
administered and the patient’s health
outcomes. It is of interest that in the case
series of neuraxial potassium chloride
administrations, approximately 50% of
errors were the consequence of misconnections.1 Administration errors that were
not due strictly to misconnection events,
even errors occurring during the perioperative period, were beyond the scope of our
current review.
We agree with Dr Patel’s assertion
that there is a need for better scales to
categorize incident harm in this context.
Our goal in using the National Reporting
and Learning System criteria5 was not to
specify which reports were representative of each level of severity, but rather to
collectively describe which drugs have the
most severe outcomes when administered
incorrectly. With regard to classifying
harm, we focused on mortality because
this is an unambiguous outcome and
represents a ‘never event’.
When assessing the efficacy of different
safety preventions, forcing functions are
at the top of the pyramid. The use of
non-
Luer neuraxial devices to prevent
the misconnection of tubing and syringes
falls into this most effective safety prevention category and cannot be defeated by
human error. Although non-Luer devices

will not prevent all administration errors,
if universally adopted, these devices could
have a substantial impact. Why do clinicians and health systems tolerate these
events when there is a ‘foolproof ’ solution
that could reduce mortality due to intravenous medication administration errors
by 50%?
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prevent misconnection and other types of
neuraxial route errors.2 3 6 These measures
are careful reading of the label on any drug
ampule or syringe, labeling all syringes,
checking labels with a second person or
a device and use of non‐Luer neuraxial
devices (NRFit devices).
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Use of transmuscular quadratus
lumborum block for
postoperative analgesia after
laparoscopic nephrectomy
To the Editor
We read with great interest the recent
article by Dam et al,1 which demonstrated
that the preoperative bilateral transmuscular quadratus lumborum block (TQLB)
significantly reduced postoperative opioid
consumption and prolonged the time to
first opioid use. We highly appreciate the
efforts and results reported in this innovative study. However, we would like to
raise one question relating to this study
that concerns about the scientific validity
of the findings and should be further
clarified.
The TQLB deposits the local anesthetic
(LA) into the lumbar fascial interspace
between the QL and psoas major (PM)
muscles. This approach allows the LA
to spread cranially under the medial and
lateral arcuate ligaments and reaches the
lower thoracic paravertebral space.2 3 In
fact, the action mechanism of the TQLB
is associated with the anatomy of the
transversalis fascia (TF). At the level of
the arcuate ligaments of the diaphragm,
the TF splits into two layers.4 One layer is
continuous with the endothoracic fascia,
and another layer becomes the inferior
diaphragmatic fascia.4 Hence, the spread
of the injectate from the lumbar injection
site into the lower thoracic paravertebral
1118

Figure 1 Schema of the retroperitoneal fascia and damage of TF during the laparoscopic
nephrectomy. (A) The TF blends with the investing fascia of QL muscle and PRF. (B) The TF damage
during laparoscopic nephrectomy was indicated by the spread of LA containing methylene blue
after the TQLB. A, aorta; ARF, anterior renal fascia; DC, descending colon; ES, erector spinae; LA,
local anesthetic; LCF, lateroconal fascia; P, pancrease; PM, psoas major; PRF, posterior renal fascia;
TF, transversalis fascia; TQLB, transmuscular quadratus lumborum block; V, vena cava.
space via the medial and lateral arcuate
ligaments with the TQLB is posterior to
the TF, and the efficient and persistent
spread of LA depends on the integrity of
the TF.
Interestingly, the TF covering the
surface of the QL and PM muscles is
blended with the investing fascia themselves (figure 1A).5 In addition, the
posterior lamina of the posterior renal
fascia may also fuse with the TF and the
blending site varies between patients, indicating the multilaminated fascial structures anterior to the QL and PM muscles
(figure 1A).5 For laparoscopic nephrectomy, the destruction of the TF, posterior
renal fascia and the investing fascia of the
QL and PM muscles are often observed
during dissection of the affected kidney.
In our pilot study, the apparent damages
to the TF were observed during laparoscopic nephrectomy in 6 out of 12 cases,
which was indicated by the spread of LA
containing methylene blue after the TQLB
(figure 1B).
The undermined integrity of the TF
may influence the efficacy of TQLB due to
LA leak from the lumbar deposit compartment into the retroperitoneal space. Even
if the block is performed preoperatively
and sufficient time is allowed for the LA
to take effect, the persistent spread of LA
from the lumbar deposit compartment
into the lower thoracic paravertebral
space via the posterior pathway of the
medial and lateral arcuate ligaments could
discontinue, and consequently, the duration of the block might be shortened.
In relation to the study of Dam et al,3
we believe that the postoperative opioid
consumption and the time to the first
opioid use in patients could be interfered

by the intraoperative damage extent of
TF. We would be interested in hearing the
authors’ thoughts on our concerns.
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